子宮頸癌為婦女最常見的癌症之一,子宮頸癌亦為台灣地區女性之最重要癌症之一。子宮頸癌有高發生率、高盛行率、高資源耗用之特性,造成子宮頸癌患者的醫療費用以及生產力的損失,對於社會產生很大的負擔及損失。 因此本研究欲計算子宮頸癌疾病之終身疾病成本,參考國外學者Brown的研究概念,以國內子宮頸癌患者為對象,估算和比較子宮頸癌以治療分期為期初、持續與臨終之疾病成本,成本內容包含其確診後的直接成本以及間接成本。 本研究之終身疾病成本架構包含直接成本和罹病成本,資料來源分為三類;健保資料庫、問卷調查及參考文獻。估計子宮頸癌患者終身醫療成本,原位癌患者之終身成本為33,587元,侵襲癌患者終身醫療成本為141,271元。 由於研究樣本平均年齡約為50歲左右,人口特質為高齡人口,因此估算之罹病成本會比直接成本較低。而終身成本中期初成本,為子宮頸癌治療過程的高峰期,因此成本比例明顯較高。期望本研究估計之子宮頸癌患者終身疾病成本能提供將來經濟評估之用,以及執行相關子宮頸癌醫療決策之參考依據。
The cervical cancer is one of women most common cancers, and the cervical cancer also is one of Taiwan female most important cancers.The cervical cancer was a high morbidity and high medical resources used disease, so the financial burden for treat cervical cancer patients and the productive loss from patients, both caused the very big burden to the society. Therefore this study objects to estimate lifetime cost of cervical cancer disease, the study method referenced Brown’s research and defined the treatment phases as initial care, terminal care, and continuing care. To estimate the cost of illness and compare the difference between the three treatment phases. The cost includes direct cost and indirect cost, and direct cost includes medical costs besides indirect cost includes morbidity cost and mortality cost. Cost data were obtained from National Health insurance Research database, questionnaire survey, and references. The lifetime cost of cervical cancer was NT$ 141,271. Hope the estimated lifetime cost of cervical cancer can provide policymakers to justify budgets, to set priorities for funding in biomedical research, and to develop intervention programmes to prevent a disease.